Skip to content

Knowledge Hub

Learn how we're pioneering a new wave of precision medicine, explore our collection of publications, disease studies, webinars, thought leadership, and more

Newsletter signup


Our Philosophy

A deep dive into our unique approach and our mission to find better treatment options for patients with unmet medical needs


Genetic Risk Factors for ME/CFS Identified using Combinatorial Analysis

New study provides the first detailed genetic insights into the mechanisms underpinning ME/CFS and offers new approaches for better diagnosis and treatments

Disease Study

COVID-19 Disease Study

Understanding the disease biology of COVID-19 to find novel drug targets and new treatment options

Disease Study

Alzheimer's Disease Study

Reducing the risk of future Alzheimer's disease clinical trial failures by identifying patient subgroups


Disease Mechanisms and Novel Target Discovery

Watch on-demand as PrecisionLife CEO, Dr Steve Gardner, joins Cyclica CEO, Naheed Kurji, to explore disease mechanisms and novel target discovery


Cell Patterns: INDx Systematic Indication Extension

Paper demonstrating the potential of indication extension to systematically reposition hundreds of drugs into new indications


Proving the Power of Combinatorial Analytics

A summary of how >70% of associated novel gene targets for severe COVID-19 identified with combinatorial analytics in May 2020 have now been independently validated


Complexity of Disease Biology Gives Opportunities for Drug Discovery

In this article, Dr Steve Gardner, CEO PrecisionLife, examines the lack of return on investment for pharmaceutical R&D and the huge pockets of unmet medical need in common chronic disorders

Disease Study

Diabetes Type 2 Complications Disease Study

Developing combinatorial risk scores to accurately predict and prevent type 2 diabetes complications

Sign Up

Subscribe to our blog